ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
15.56 USD
-0.14 (-0.89%)
15.56 USD
0 (0%)
ADMA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is evaluated to be cheap and growing strongly. This does not happen too often! This makes ADMA very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 37.42%, ADMA belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
ADMA has a Return On Equity of 52.45%. This is amongst the best in the industry. ADMA outperforms 98.49% of its industry peers.
ADMA has a better Return On Invested Capital (25.43%) than 98.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 44.06%, ADMA belongs to the best of the industry, outperforming 98.12% of the companies in the same industry.
ADMA's Operating Margin of 32.82% is amongst the best of the industry. ADMA outperforms 97.18% of its industry peers.
ADMA's Gross Margin of 53.00% is fine compared to the rest of the industry. ADMA outperforms 75.89% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
ADMA has an Altman-Z score of 15.89. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA has a better Altman-Z score (15.89) than 88.51% of its industry peers.
The Debt to FCF ratio of ADMA is 1.12, which is an excellent value as it means it would take ADMA, only 1.12 years of fcf income to pay off all of its debts.
ADMA has a better Debt to FCF ratio (1.12) than 93.79% of its industry peers.
ADMA has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.18, ADMA is doing worse than 67.04% of the companies in the same industry.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 15.89 |
ROIC/WACC2.91
WACC8.74%
2.3 Liquidity
A Current Ratio of 5.33 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a Current ratio of 5.33. This is comparable to the rest of the industry: ADMA outperforms 58.95% of its industry peers.
A Quick Ratio of 2.78 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Quick ratio of 2.78 is on the low side compared to the rest of the industry. ADMA is outperformed by 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.86% over the past year.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 65.15%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
The Earnings Per Share is expected to grow by 32.01% on average over the next years. This is a very strong growth
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.94% yearly.
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 28.81, ADMA can be considered very expensive at the moment.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 92.28% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.91. ADMA is around the same levels.
With a Price/Forward Earnings ratio of 16.45, ADMA is valued correctly.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.16% of the companies in the same industry.
ADMA is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.81 | ||
| Fwd PE | 16.45 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.03% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 91.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.59 | ||
| EV/EBITDA | 22.8 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
ADMA's earnings are expected to grow with 35.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.37
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y35.8%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.56
-0.14 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change-1.9%
Ins Owners2.35%
Ins Owner Change-0.83%
Market Cap3.71B
Revenue(TTM)426.45M
Net Income(TTM)208.93M
Analysts84
Price Target27.8 (78.66%)
Short Float %7.67%
Short Ratio5.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)-6.23%
PT rev (3m)-6.23%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-10%
EPS NY rev (1m)4.7%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)-0.51%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.81 | ||
| Fwd PE | 16.45 | ||
| P/S | 7.83 | ||
| P/FCF | 56.59 | ||
| P/OCF | 48.41 | ||
| P/B | 9.32 | ||
| P/tB | 9.42 | ||
| EV/EBITDA | 22.8 |
EPS(TTM)0.54
EY3.47%
EPS(NY)0.95
Fwd EY6.08%
FCF(TTM)0.27
FCFY1.77%
OCF(TTM)0.32
OCFY2.07%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.37
PEG (5Y)N/A
Graham Number4.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 15.89 |
F-Score5
WACC8.74%
ROIC/WACC2.91
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.11%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 6 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 28.81 and the Price/Book (PB) ratio is 9.32.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.